Lead Product(s) : DNL758
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Denali Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Sanofi Begins Dosing of DNL758 in Phase Ib Covid-19 Trial
Details : Dosing of DNL758 has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19.
Brand Name : SAR443122
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 30, 2020
Lead Product(s) : DNL758
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Denali Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DNL758
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19.
Brand Name : SAR443122
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2020
Lead Product(s) : DNL758
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?